• Hepatitis Delta Connect

• News Archive
• Newly Diagnosed
• What is Hepatitis Delta?
• Facts and Figures
• Transmission
• 
  Testing and Diagnosis
  • Hepatitis Delta Testing Program
• Prevention
• Symptoms
• Treatment
• Drug Watch
• Clinical Trials
• Find A Doctor
• 
  Resources
  • Printable Fact Sheets (English)
  • Printable Fact Sheets (Romanian)
  • Printable Fact Sheets (Russian)
  • Printable Fact Sheets (Spanish)
  • Printable Fact Sheets (Mongolian)
  • Blog Posts
  • Presentations
• Webinars
• FAQ
• Contact Us
• Share Your Story

News Archive

06/25/2021: Gilead Preps Filing for Hepatitis D Therapy Hepcludex in US

06/24/2021: Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks

04/01/2021: Hepatitis Delta Infection Among Persons with HIV in Europe

11/30/20: New Insights into Hepatitis D Virus Persistence: The Role of Interferon Response and Implications for Upcoming Novel Therapies

11/17/20: Eiger Announces Positive Peginterferon Lambda-Lonafarnib Combination End-of-Study Results from Phase 2 LIFT HDV Study at the Liver Meeting Digital Experience 2020

11/16/20: Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic HDV Infection at the Liver Meeting Digital Experience 2020

10/7/20: Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened? 

9/17/20: Hepcludex Launched in Germany, France, and Austria

8/31/20: End of Treatment Results Presented for Lambda-Interferon + Lonafarnib Combination Phase 2 LIFT Study at International Liver Congress, 2020

8/5/20: Hepcludex Approved by European Commission

6/2/20: MYR Pharmaceuticals Receives Positive Opinion from EMA for Hepcludex for the Treatment of Chronic Hepatitis Delta

2/18/20: New Insights into Hepatitis B and Hepatitis Delta Virus Entry

2/1/20: The Effect of Twelve Weeks of Treatment with Ezetimibe on HDV RNA Level in Patients with Chronic Hepatitis D

1/2/20: Hepatitis Delta Has Higher Health Care Cost Burden Than Hepatitis B

12/26/19: REP2139 Demonstrates Functional Cure in Both HBV, HDV 

11/12/19: Eiger Announces Phase 2 LIFT Study Results During AASLD 2019

11/1/19: MYR Pharmaceuticals to Present on Myrcludex B During AASLD 2019

11/1/19: FDA Guidance to Help with Hepatitis Delta Drug Development

8/20/19: Pegylated Interferon Lambda Receives FDA Breakthrough Therapy Designation

7/29/19: Russia Plans Production of Myrcludex B

4/13/19: MYR Announces Phase 2 Myrcludex B Trial Data at The International Liver Congress 2019

4/11/19: Eiger Announces Phase 2 LIMT Hepatitis Delta Study Progress at The International Liver Congress 2019

3/5/19: MYR Pharma Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Myrcludex B

12/18/18: Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib

12/17/18: Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib

9/28/18: Global Hepatitis Delta Rates Highest Among HBV Coinfected with Risky Behaviors

6/4/18: Digestive Disease Week: Hepatitis Delta: The 'Forgotten Virus' is Still Here

10/23/18: MYR Pharma Announces FDA Breakthrough Therapy Designation for Myrcludex B

9/5/17:  Pegylated Interferon Lambda Receives FDA Orphan Drug Designation

7/27/17: Pegylated Interferon Lambda Receives FDA Fast Track Designation 

5/25/17: MYR Pharma Announces Myrcludex B PRIME Designation by the EMA

12/23/14: EB Pharma Announces License Agreement for Tipifarnib from Janssen Pharmaceutica for Development in Hepatitis Delta 

12/22/14: Lonafarnib Recieves Orphan Drug Designation by FDA and EMA